Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Transarterial Chemoembolization Using Gelatin Sponges or Microspheres Plus Lipiodol-Doxorubicin versus Doxorubicin-Loaded Beads for the Treatment of Hepatocellular Carcinoma

  • Liu, Yi-Sheng (Department of Diagnostic Radiology, National Cheng-Kung University Hospital) ;
  • Ou, Ming-Ching (Department of Diagnostic Radiology, National Cheng-Kung University Hospital) ;
  • Tsai, Yi-Shan (Department of Diagnostic Radiology, National Cheng-Kung University Hospital) ;
  • Lin, Xi-Zhang (Liver Cancer Collaborative Oncology Group, National Cheng-Kung University Hospital) ;
  • Wang, Chien-Kuo (Department of Diagnostic Radiology, National Cheng-Kung University Hospital) ;
  • Tsai, Hong-Ming (Department of Diagnostic Radiology, National Cheng-Kung University Hospital) ;
  • Chuang, Ming-Tsung (Department of Diagnostic Radiology, National Cheng-Kung University Hospital)
  • Received : 2014.03.28
  • Accepted : 2014.09.25
  • Published : 2015.02.01
⟨ Previous Next ⟩

Abstract

Objective: To retrospectively compare treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) using gelatin sponges or microspheres plus lipiodol-doxorubicin vs. doxorubicin-loaded drug-eluting beads (DEB). Materials and Methods: A total of 158 patients with HCC received TACE from November 2010 to November 2011 were enrolled in this study, including 64 (40.5%) received TACE with lipiodol-doxorubicin and gelatin sponges (group A), 41 (25.9%) received TACE with lipiodol-doxorubicin and microspheres (group B), and 53 (33.5%) received TACE with doxorubicin-loaded DEB (group C). Tumor response and adverse events (AEs) were evaluated. Results: No significant difference was found at baseline among the three groups. The doxorubicin dosage in group C was significantly (p < 0.001) higher compared to the dose used in groups A or B (median, 50 mg vs. 31 mg or 25 mg). Significantly (p < 0.001) more patients in group C achieved complete response compared to those in groups A or B (32.1% vs. 6.3% or 2.4%). Significantly (p < 0.001) less patients in group C had progressive disease compared to those in groups A or B (34.0% vs. 57.8% or 68.3%). Minor AEs were more common in groups A and B compared to group C, with rates of 54.7%, 34.1%, and 5.7%, respectively. Conclusion: In patients with HCC, TACE with DEB offers better safety and efficacy profiles compared to either TACE with gelatin sponges or TACE with microspheres.

Keywords

References

  1. Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010;255:955-965 https://doi.org/10.1148/radiol.10091473
  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90 https://doi.org/10.3322/caac.20107
  3. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011;253:745-758 https://doi.org/10.1097/SLA.0b013e3182111195
  4. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236 https://doi.org/10.1002/hep.20933
  5. Wu KT, Wang CC, Lu LG, Zhang WD, Zhang FJ, Shi F, et al. Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities. World J Gastroenterol 2013;19:3649-3657 https://doi.org/10.3748/wjg.v19.i23.3649
  6. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917 https://doi.org/10.1016/S0140-6736(03)14964-1
  7. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25 https://doi.org/10.1007/s00270-006-0062-3
  8. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010;28:3994-4005 https://doi.org/10.1200/JCO.2010.28.7805
  9. Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13(9 Pt 2):S211-S221 https://doi.org/10.1016/S1051-0443(07)61789-8
  10. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442 https://doi.org/10.1053/jhep.2003.50047
  11. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711 https://doi.org/10.1093/jnci/djn134
  12. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-773 https://doi.org/10.1002/hep.23725
  13. Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009;20(7 Suppl):S425-S434 https://doi.org/10.1016/j.jvir.2009.04.021
  14. Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 2012;35:980-985 https://doi.org/10.1007/s00270-011-0287-7
  15. Song MJ, Park CH, Kim JD, Kim HY, Bae SH, Choi JY, et al. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol 2011;23:521-527 https://doi.org/10.1097/MEG.0b013e328346d505
  16. Poyanli A, Rozanes I, Acunas B, Sencer S. Palliative treatment of hepatocellular carcinoma by chemoembolization. Acta Radiol 2001;42:602-607 https://doi.org/10.1080/028418501127347278
  17. Lee JK, Chung YH, Song BC, Shin JW, Choi WB, Yang SH, et al. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol 2002;17:52-58 https://doi.org/10.1046/j.1440-1746.2002.02664.x
  18. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007;5:1100-1108 https://doi.org/10.1016/j.cgh.2007.04.021
  19. Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010;21:327-332 https://doi.org/10.1016/j.jvir.2009.10.038
  20. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474-481 https://doi.org/10.1016/j.jhep.2006.10.020
  21. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52 https://doi.org/10.1007/s00270-009-9711-7
  22. Granberg D, Eriksson LG, Welin S, Kindmark H, Janson ET, Skogseid B, et al. Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors. Acta Radiol 2007;48:180-185 https://doi.org/10.1080/02841850601080440
  23. Covey AM, Brody LA, Maluccio MA, Getrajdman GI, Brown KT. Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology 2002;224:542-547 https://doi.org/10.1148/radiol.2242011283
  24. de Baere T, Zhang X, Aubert B, Harry G, Lagrange C, Ropers J, et al. Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. Radiology 1996;201:731-735 https://doi.org/10.1148/radiology.201.3.8939223
  25. Idee JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol 2013;88:530-549 https://doi.org/10.1016/j.critrevonc.2013.07.003
  26. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60 https://doi.org/10.1055/s-0030-1247132
  27. Graf D, Vallbohmer D, Knoefel WT, Kropil P, Antoch G, Sagir A, et al. Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med 2014;25:430-437 https://doi.org/10.1016/j.ejim.2014.03.001
  28. Cardella JF, Kundu S, Miller DL, Millward SF, Sacks D; Society of Interventional Radiology. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 2009;20(7 Suppl):S189-S191 https://doi.org/10.1016/j.jvir.2009.04.035
  29. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170(3 Pt 1):783-786 https://doi.org/10.1148/radiology.170.3.2536946
  30. Malagari K, Alexopoulou E, Chatzimichail K, Hall B, Koskinas J, Ryan S, et al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 2008;33:512-519 https://doi.org/10.1007/s00261-007-9334-x
  31. Song do S, Choi JY, Yoo SH, Kim HY, Song MJ, Bae SH, et al. DC bead transarterial chemoembolization is effective in hepatocellular carcinoma refractory to conventional transarteral chemoembolization: a pilot study. Gut Liver 2013;7:89-95 https://doi.org/10.5009/gnl.2013.7.1.89
  32. Kalva SP, Pectasides M, Liu R, Rachamreddy N, Surakanti S, Yeddula K, et al. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol 2014;37:381-387 https://doi.org/10.1007/s00270-013-0654-7
  33. Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011;22:1545-1552 https://doi.org/10.1016/j.jvir.2011.07.002
  34. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010;101:476-480
  35. Malagari K, Pomoni M, Spyridopoulos TN, Moschouris H, Kelekis A, Dourakis S, et al. Safety profile of sequential transcatheter chemoembolization with DC $Bead^{TM}$: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol 2011;34:774-785 https://doi.org/10.1007/s00270-010-0044-3
  36. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006;12:2563-2567 https://doi.org/10.1158/1078-0432.CCR-05-2225
  37. Wigmore SJ, Redhead DN, Thomson BN, Currie EJ, Parks RW, Madhavan KK, et al. Postchemoembolisation syndrome--tumour necrosis or hepatocyte injury? Br J Cancer 2003;89:1423-1427 https://doi.org/10.1038/sj.bjc.6601329
  38. Recchia F, Passalacqua G, Filauri P, Doddi M, Boscarato P, Candeloro G, et al. Chemoembolization of unresectable hepatocellular carcinoma: decreased toxicity with slow-release doxorubicineluting beads compared with lipiodol. Oncol Rep 2012;27:1377-1383
  39. Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 2011;197:W562-W570 https://doi.org/10.2214/AJR.10.4379
  40. Lopez-Benitez R, Radeleff BA, Barragan-Campos HM, Noeldge G, Grenacher L, Richter GM, et al. Acute pancreatitis after embolization of liver tumors: frequency and associated risk factors. Pancreatology 2007;7:53-62 https://doi.org/10.1159/000101878

Cited by

  1. Optimized Performance of FlightPlan during Chemoembolization for Hepatocellular Carcinoma: Importance of the Proportion of Segmented Tumor Area vol.17, pp.5, 2015, https://doi.org/10.3348/kjr.2016.17.5.771
  2. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma vol.18, pp.None, 2015, https://doi.org/10.1186/s12876-018-0848-1
  3. Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodu vol.19, pp.2, 2018, https://doi.org/10.3348/kjr.2018.19.2.237
  4. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art vol.24, pp.2, 2015, https://doi.org/10.3748/wjg.v24.i2.161
  5. Developing a Roadmap for Interventional Oncology vol.23, pp.10, 2018, https://doi.org/10.1634/theoncologist.2017-0654
  6. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients vol.18, pp.None, 2015, https://doi.org/10.1186/s12885-018-4566-4
  7. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study vol.16, pp.None, 2015, https://doi.org/10.1186/s12957-018-1368-8
  8. Recent advances in medical management of hepatocellular carcinoma vol.49, pp.1, 2015, https://doi.org/10.1111/hepr.13259
  9. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma vol.20, pp.1, 2015, https://doi.org/10.3348/kjr.2018.0088
  10. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting vol.54, pp.7, 2015, https://doi.org/10.1080/00365521.2019.1632925
  11. The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A m vol.13, pp.5, 2019, https://doi.org/10.5582/bst.2019.01153
  12. Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients : A preliminary result from CTILC study vol.99, pp.12, 2020, https://doi.org/10.1097/md.0000000000019276
  13. Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition) vol.9, pp.1, 2015, https://doi.org/10.1159/000503685
  14. Drug-eluting Bead-Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma Refractory to Conventional Lipiodol-based Transcatheter Arterial Chemoembolization vol.7, pp.None, 2015, https://doi.org/10.2147/jhc.s273929
  15. Is it Rational to Perform Liver Resection for Patients with Intermediate and Advanced Stages of Hepatocellular Carcinoma? vol.86, pp.4, 2015, https://doi.org/10.1177/000313482008600427
  16. Timeline of Translational Formulation Technologies for Cancer Therapy: Successes, Failures, and Lessons Learned Therefrom vol.12, pp.11, 2015, https://doi.org/10.3390/pharmaceutics12111028
  17. Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival-prospective interventional study vol.5, pp.1, 2015, https://doi.org/10.1186/s41747-021-00204-6